BioSpace News Archive

Todos Medical, Ltd. today announced it is now adding the Hillel Yaffe Medical Center as the 2nd clinical trial site in Hadera, Israel for its ongoing Tollovir® Phase 2 randomized, double blind, placebo controlled clinical trial for the treatment of hospitalized COVID-19 patients.

Cyteir Therapeutics, Inc. announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a presentation at the Credit Suisse 30th Annual Healthcare Conference, being held virtually on November 8, 2021, at 4:20pm ET.

Miravo Healthcare™ Announces Third Quarter 2021 Results Release Date and Conference Call Details

Immatics N.V. today announced that the company will provide an update on its ACTengine® IMA203 trial in a late-breaking oral presentation as well as an update on Immatics’ next-generation CD8ab TCR-T approach at the 36th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC).

Eledon Pharmaceuticals today announced that it plans to release financial results for the third quarter ended September 30, 2021 on Thursday, November 11, after the close of trading

Chimerix today announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference on Monday, November 8, 2021 at 9:40 a.m. ET.

Kiniksa Pharmaceuticals, Ltd. today reported third quarter 2021 financial results and recent portfolio execution.

Kinnate Biopharma Inc. today announced a collaboration with Guardant Health, a leading precision oncology company, focused on characterizing the prevalence of patients with advanced solid tumors bearing BRAF Class I, II and III alterations.

Novartis announced today that the US Food and Drug Administration (FDA) approved Scemblix® (asciminib) for the treatment of chronic myeloid leukemia (CML) in two distinct indications.

Tarveda Therapeutics, Inc., which it refers to as Pentarin® miniature drug conjugates, today announced that data from the Phase 2 clinical trial of PEN-221 will be presented at the North American Neuroendocrine Tumor Society (NANETS) 2021 Multidisciplinary NET Medical Virtual Symposium occurring November 3-6, 2021.